The future trajectory of the is inextricably linked to the 'Zero by 30' initiative—the global goal to eliminate dog-mediated human rabies deaths by 2030. This ambitious target necessitates a massive scale-up of both vaccination programs and diagnostic surveillance worldwide. The Rabies Diagnostics Market forecast projects substantial growth, with market valuation expected to increase significantly over the coming years, driven by a projected Compound Annual Growth Rate (CAGR) fueled by this elimination imperative. A key driver of this growth will be the continuous push for improved diagnostics in endemic regions, primarily Asia-Pacific and Africa, which bear the brunt of the global disease burden. The demand will pivot towards solutions that are not only highly accurate but also cost-effective and suitable for use in veterinary and public health field settings.

Technological innovation is forecast to play a pivotal role, particularly in the realm of rapid, point-of-care (PoC) testing. While laboratory-based methods like FAT and PCR will remain crucial for confirmation and surveillance, the market will increasingly favor fast, simple diagnostic kits that can be utilized by field workers for immediate animal testing. Furthermore, a rising focus on companion animal health, coupled with increased pet ownership and mandated vaccination programs in developed regions, will sustain the demand for serological assays, used to monitor vaccine efficacy and antibody levels. The interplay between human and animal health sectors—known as the One Health approach—is becoming a fundamental framework for rabies control, ensuring that diagnostics for both populations are developed in tandem, thereby creating new market opportunities for cross-sector applications and collaborative development.